Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787618 · ClinicalTrials.gov registry record · Phase 1
Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females
A Phase 1 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00787618 is a Phase 1 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT00787618, a Phase 1 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
PK and safety profile of Proellex® in females with various stages of impaired renal function
Interventions
- DRUG 50 mg Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787618
The ClinicalTrials.gov registry entry for NCT00787618 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 50 mg Proellex is the first listed.
NCT00787618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787618 about?
NCT00787618 is a clinical study titled "Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females". PK and safety profile of Proellex® in females with various stages of impaired renal function
What is the current status of trial NCT00787618?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2008-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00787618?
The interventions under investigation include: 50 mg Proellex (DRUG).
Who is sponsoring clinical trial NCT00787618?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.